EDF Health

What I Learned from Theo Colborn

Sarah Vogel, Ph.Dis Director of EDF's Health Program.

It was late September and we were driving up and over the Kebler Pass, which takes you from the dry desert environment of the Western Slope of the Rocky Mountains near Paonia, Colorado to the high mountain town of Crested Butte. We traveled through green meadows up through groves of quaking aspens, bright gold at the higher altitudes, up towards the pass, already covered in snow, blindingly bright under a brilliant Colorado sun and clear blue sky.

These were the mountain ranges where Theo Colborn, scientist and environmental health advocate, began her studies; where she lived for much of her life; the mountains that she loved; where she recently passed away at 87 years of remarkable age; and, where I suspect her spirit now resides.

Read More »

Posted in Uncategorized| Tagged , | 1 Response

EPA IRIS program requests conflict-of-interest disclosures by commenters

Richard Denison, Ph.D.is a Lead Senior Scientist.  Lindsay McCormick is a Research Analyst

EPA’s Integrated Risk Information System (IRIS) is now requesting that persons who make oral comments at its bimonthly meetings or submit written comments on its documents disclose whether they have “financial relationships … with any organization(s) or entities having an interest in the assessments or issues under discussion,” and, if so, to identify the nature of that relationship, (e.g., consulting agreements, expert witness support, or research funding).   Read More »

Posted in Health Policy, Industry Influence| Tagged , | Comments closed

Whither TSCA reform post-election?

Richard Denison, Ph.D., is a Lead Senior Scientist.

[This post is adapted from comments I gave at a recent Friday Forum hosted by the American Bar Association’s Pesticides, Chemical Regulation and Right-to-Know Committee.]

Elections change some things and don’t change others.  That is certainly true about what happened on Nov 4.

The best election recap I’ve heard came from a hairdresser I overhead when getting my hair cut last week.  She said:  “Democrats win, I have to work; Republicans win, I have to work.”

I doubt anyone would try to argue that the election was in any way about or directly relevant to the TSCA reform debate, or even any sort of more general referendum on the environment.  My view is that it wasn’t really even much about political parties and which one controls the Senate – it was more of a “throw the bums out and let some new ones have a try” election.

On the other hand, it was about broad and deep dissatisfaction of voters with the inability of Washington to get anything meaningful done.  That is relevant to the opportunity the TSCA reform issue presents to the new Congress, which is one of a handful of issues that seems to have the potential to show voters that something can get done.

There is also no question that the dynamics that have determined for some time the pace and direction of the TSCA reform debate changed significantly with the switch to Republican control of the Senate. That brings with it new political opportunities and challenges.

But what I want to talk mostly about is what HASN’T changed.  Read More »

Posted in Health Policy, TSCA Reform| Tagged | Comments closed

EDF’s recommendations for IRIS conflicts-of-interest disclosures, and the strong precedents for them

Richard Denison, Ph.D., is a Lead Senior Scientist.  Lindsay McCormick is a Research Analyst

Our last blog post was quite lengthy and some readers may not have gotten to the recommendations we provided to EPA’s Integrated Risk Information System (IRIS) governing disclosures of conflicts of interest.  In that post, we also cited the numerous strong precedents for requiring such disclosures.

So we’re reposting here our recommendations and discussion of precedents.   Read More »

Posted in Health Policy, Industry Influence| Tagged , , | Comments closed

Time to come clean: IRIS needs to require stakeholders attending its meetings to disclose their conflicts of interest

Richard Denison, Ph.D., is a Lead Senior Scientist.  Lindsay McCormick is a Research Analyst.  

EPA’s Integrated Risk Information System (IRIS) has been implementing a number of changes in the last couple of years, in response to criticism and concerns coming at it from all sides.  As stated on its website:  “These enhancements will improve productivity and scientific quality in IRIS assessments and help EPA meet the goal of producing IRIS assessments in a timely and transparent manner.”  IRIS has noted that increasing “stakeholder engagement is an essential part of the enhancements.”

Simultaneously pursuing these lofty goals of increasing throughput, scientific quality, transparency and stakeholder engagement in IRIS assessments is challenging, to say the least.  EDF has and will continue to emphasize the need to strike a balance between these goals, given that overemphasis on one can actually exacerbate the problems aimed to be addressed by another.

In this somewhat lengthy post, we’ll examine one such serious problem – skewed participation in IRIS’ bimonthly meetings.  We’ll look at steps EPA has taken to partially address the problem, and argue that the lack of adequate disclosure by participants of conflicts of interest remains a major unaddressed contributing factor.  We’ll discuss our recommendations for full disclosure and point to the strong precedents for such disclosures in other venues.   Read More »

Posted in EPA, Health Policy, Industry Influence| Tagged , , | Comments closed

Will 2015 be the year of full product ingredient disclosure?

Richard Denison, Ph.D., is a Lead Senior Scientist.

Michelle Harvey, Jennifer McPartland and Boma Brown-West contributed to this post.

[UPDATE 10/28/14:  This post has been updated to reflect information we learned since posting it, regarding additional companies' disclosure initiatives.]

We are nowhere near New Year’s Day, but based on recent corporate resolutions, 2015 is shaping up to be the year for ingredient transparency in products!  And that’s good news for those of us who want to know what we may be exposing ourselves and our families to when we use everyday products in our homes and on our bodies.

Unlike food and drugs, which must bear content labels, there has all too often been no way for consumers to know what’s in the products they use.  In particular, the composition of the myriad fragrances used in household cleaners, detergents and soaps, air fresheners, and other common household products have pretty much been a black box.  But change is on the way.   Read More »

Posted in Health Policy, Markets and Retail| Tagged | Comments closed
  • About this blog


    Science, health, and business experts at Environmental Defense Fund comment on chemical and nanotechnology issues of the day.
    Our work: Chemicals
  • Categories

  • Get blog posts by email

    Subscribe via RSS

  • Filter posts by tags

    • aggregate exposure (10)
    • Alternatives assessment (3)
    • American Chemistry Council (ACC) (57)
    • arsenic (3)
    • asthma (3)
    • Australia (1)
    • biomonitoring (9)
    • bipartisan (6)
    • bisphenol A (20)
    • BP Oil Disaster (18)
    • California (1)
    • Canada (7)
    • carbon nanotubes (24)
    • carcinogen (22)
    • Carcinogenic Mutagenic or Toxic for Reproduction (CMR) (12)
    • CDC (6)
    • Chemical Assessment and Management Program (ChAMP) (13)
    • chemical identity (30)
    • chemical testing (1)
    • Chemicals in Commerce Act (3)
    • Chicago Tribune (6)
    • children's safety (23)
    • China (10)
    • computational toxicology (11)
    • Confidential Business Information (CBI) (53)
    • conflict of interest (7)
    • consumer products (48)
    • Consumer Specialty Products Association (CSPA) (4)
    • contamination (4)
    • cumulative exposure (4)
    • data requirements (46)
    • dermal exposure (1)
    • diabetes (4)
    • DNA methylation (4)
    • DuPont (11)
    • endocrine disruption (29)
    • epigenetics (4)
    • exposure and hazard (49)
    • FDA (8)
    • flame retardants (20)
    • formaldehyde (15)
    • front group (13)
    • general interest (22)
    • Globally Harmonized System (GHS) (5)
    • Government Accountability Office (5)
    • hazard (6)
    • High Production Volume (HPV) (22)
    • in vitro (14)
    • in vivo (11)
    • industry tactics (44)
    • informed substitution (1)
    • inhalation (18)
    • IUR/CDR (27)
    • Japan (3)
    • lead (6)
    • markets (1)
    • mercury (4)
    • methylmercury (2)
    • microbiome (3)
    • nanosilver (6)
    • National Academy of Sciences (NAS) (20)
    • National Institute for Occupational Safety and Health (NIOSH) (7)
    • National Institute of Environmental Health Sciences (NIEHS) (5)
    • National Nanotechnology Initiative (NNI) (7)
    • National Toxicology Program (1)
    • obesity (6)
    • Occupational Safety and Health Administration (OSHA) (3)
    • Office of Information and Regulatory Affairs (OIRA) (4)
    • Office of Management and Budget (OMB) (16)
    • Office of Pollution Prevention and Toxics (OPPT) (3)
    • oil dispersant (18)
    • PBDEs (16)
    • Persistent Bioaccumulative and Toxic (PBT) (22)
    • pesticides (7)
    • phthalates (17)
    • polycyclic aromatic hydrocarbons (PAH) (5)
    • prenatal (6)
    • prioritization (35)
    • report on carcinogens (1)
    • revised CSIA (4)
    • risk assessment (69)
    • Safe Chemicals Act (24)
    • Safer Chemicals Healthy Families (33)
    • Significant New Use Rule (SNUR) (20)
    • Small business (1)
    • South Korea (4)
    • styrene (6)
    • Substances of Very High Concern (SVHC) (15)
    • systematic review (1)
    • test rule (17)
    • tributyltin (3)
    • trichloroethylene (TCE) (3)
    • Turkey (3)
    • U.S. states (14)
    • vulnerable populations (1)
    • Walmart (2)
    • worker safety (23)
    • WV chemical spill (11)